Quinolone antibiotics: A potential adjunct to intravesical chemotherapy for bladder cancer

Urology

Volumn 54, Issue 1, 1999, Pages 56-61

  Kamat, Ashish M ^a   Dehaven, Jean I ^a   Lamm, Donald L ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXORUBICIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; CANCER RECURRENCE; COLORIMETRY; CYTOTOXICITY; HUMAN; HUMAN CELL; INTRAVESICAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; HUMANS; OFLOXACIN; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033168775     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00064-3     Document Type: Article

References (29)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics. CA Cancer J Clin 48: 6-29, 1998.
2. Lamm DL, and Griffith JG: Intravesical therapy: does it affect the natural history of bladder cancer? Semin Urol 10: 39-44, 1992.
3. Bostwick DG: Natural history of early bladder cancer. J Cell Biochem Suppl 161: 31-38, 1992.
4. Rubben H, Lutzeyer W, Fischer N, et al: Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139: 283-285, 1988.
5. Lamm DL, Riggs DR, Traynelis CL, et al: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153: 1444-1450, 1995.
6. Campoli-Richards DM, Monk JP, Price A, et al: Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic and therapeutic use. Drugs 35: 373-447, 1988.
7. Malonne H, and Atassi G: DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs 8: 811-822, 1997.
8. Bubenick J, Baresora M, Viklicky V, et al: Established cell line of urinary bladder carcinoma (T24) containing tumor-specific antigen. Int J Cancer 11: 765-773, 1973.
9. Catalona WJ, Oldham RK, Djeu JY, et al: Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24. Surg Forum 26: 122-124, 1975.
10. Nayak SK, O'Toole C, and Price ZH: A cell line from an anaplastic transitional cell carcinoma of human urinary bladder. Br J Cancer 35: 142-151, 1977.
11. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
12. Fritzer-Szekeres M, Novotny L, Romanova D, et al: Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia. Life Sci 63: 545-552, 1998.
13. Seay TM, Peretsman SJ, and Dixon PS: Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 155: 757-762, 1996.
14. Gasser TC: Quinolone prophylaxis in transurethral surgery. Chemotherapy Suppl 1: 28-32, 1996.
15. Hussy P, Maass G, Tummler B, et al: Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases 1 and 11, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 29: 1073-1078, 1986.
16. Larsen AK, Skladanowski A, and Bojanowski K: The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res 2: 229-239, 1996.
17. Zehavi-Willner T, and Shalit I: The inhibitory effect of ciprofloxacin on proliferation of a murine bladder carcinoma cell line. J Antimicrob Chemother 29: 323-328, 1992.
18. Ebisuno S, Inagaki T, Kohjimoto Y, et al: The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 80: 2263-2267, 1997.
19. Miclau T, Edin ML, Lester GE, et al: Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 16: 509-512, 1998.
20. Sarkis AS, Bajorin DE, Reuter VE, et al: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13: 1384-1390, 1995.
21. Lacombe L, Dalbagni G, Zhang ZF, et al: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol 14: 2646-2652, 1996.
22. Ye D, Li H, Qian S, et al: Bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J Urol 160: 2025-2028, 1998.
23. Gan Y, Wientjes MG, Badalament RA, et al: Pharmacodynamics of doxorubicin in human bladder tumors. Clin Cancer Res 2: 1275-1283, 1996.
24. Gonzalez MA, Uribe F, Moisen SD, et al: Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26: 741-744, 1984.
25. Monk JP, and Campoli-Richards DM: Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 33: 346-391, 1987.
26. Yuk JH, Nightingale CH, Quintiliani R, et al: Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother 35: 384-386, 1991.
27. Tsushima T, Miyaji Y, Noda M, et al: Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. Urol Int 60: 161-164, 1998.
28. Brausi M, Campo B, Pizzocaro G, et al: Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase 11 study. Urology 51: 506-509, 1998.
29. Okuno H, Kakehi Y, Ozdemir E, et al: Association of in vitro growth potential of urinary exfoliated cells with tumor localization and intraluminal recurrence rates of urothelial cancers. J Urol 158: 1996-1999, 1997.